Epidemiological studies have shown that low plasma levels of High Density Lipoprotein Cholesterol (HDL-C) are associated with an increased risk for myocardial infarction. These studies suggested that by increasing HDL-C levels one could reduce cardiovascular risk. However, emerging evidence from studies in animals and humans indicate that high levels of HDL-C are not sufficient to confer atheroprotection but that the functionality of the HDL particles is equally important. The picture is complicated further by the finding that HDL functionality is compromised in patients with chronic inflammatory diseases such as Coronary Artery Disease (CAD), diabetes and rheumatoid arthritis. Despite these obstacles, HDL raising is still a promising strategy for the reduction of CAD risk. Low HDL-C can be caused by inactivating mutations in apoA-I, ATP Binding Cassette Transporter A1 (ABCA1) or Lecithin-Cholesterol Acyl Transferase (LCAT) which affect HDL biogenesis and maturation whereas high HDL-C can be caused by mutations in Cholesteryl Ester Transfer Protein (CETP) or Scavenger receptor Class B Type I (SR-BI). Recent studies suggest that heterogeneity in HDL levels in the population is polygenic in origin. One approach to raise plasma HDL-C is to increase the rate of HDL biosynthesis by capitalizing on the mechanisms that control the transcription of genes that play key roles in HDL biogenesis. We review some of the genetic and non-genetic factors that affect plasma HDL levels and functions and discuss the mechanisms that regulate HDL metabolism at the level of gene transcription in the liver focusing on apoA-I, ABCA1 and apoM.
HDL metabolism begins in the liver and in the intestine. Lipid-free apolipoprotein A-I (apoA-I), which is produced and secreted by the above tissues, interacts physically and extracellularly with the membrane lipid transporter ATP Binding Cassette Transporter A1 (ABCA1) and this interaction promotes the transfer of phospholipids and cholesterol to apoA-I thus forming lipid-poor apoA-I [1] . These lipidpoor apoA-I particles acquire additional phospholipids and cholesterol from peripheral cells such as the macrophages of the arterial wall via interaction with ABCA1 and are converted first to discoidal pre-HDL and subsequently to spherical HDL, via the action of the enzyme LCAT (Lecithin:Cholesterol Acyl Transferase). The recently identified apolipoprotein M (apoM) which associates with HDL as well as with LDL, also contributes to HDL remodeling as revealed by experiments in mice but the mechanisms still remain unknown [2] . HDL particles can also be generated by similar mechanisms via the action of other apolipoproteins including apoE and apoA-IV as demonstrated in apoA-I -/-mice using adenovirus-mediated gene transfer [3, 4] . The functionality of these HDL-E or HDL-A-IV particles (which are mainly formed in the absence of apoA-I) and their contribution to HDL-mediated atheroprotection under physiological or pathological conditions is still a subject of *Address correspondence to this author at the Department of Basic Sciences, University of Crete Medical School, Heraklion 71003 Greece; Tel: +30-2810-394549; Fax: +30-2810-394530; E-mail: kardasis@imbb.forth.gr investigation. Finally, -HDL particles are remodeled by the Scavenger Receptor class B type I (SR-BI) [5] which facilitates selective cholesterol ester uptake by the liver (for secretion into the bile via the ABCG5/G8 transporters) or by the adrenal cells (for the synthesis of steroid hormones). While the majority of bile acids are reabsorbed in the intestine, a proportion is eliminated in the feces, thereby ridding the body of excess cholesterol [6] . Remodeling of HDL particles is also facilitated by the ABCG1 transporter (and the SR-BI) in macrophages which promotes the efflux of cellular cholesterol to mature spherical -HDL particles and by the hydrolysis of HDL lipids by lipases such as the lipoprotein lipase (LPL), the hepatic lipase (LIPC) and the endothelial lipase (LIPG) [7] . Exchange of lipids between HDL particles and apoB-containing lipoproteins (VLDL, LDL) is facilitated by the phospholipid transfer protein (PLTP) and the cholesterol ester transfer protein (CETP) regenerating the pre-HDL particles that initiate another cycle of HDL maturation and remodeling via the mechanisms described above [8] .
Cholesterol from HDL can also be transported back to the intestine via a process called TICE (Trans Intestinal Cholesterol Efflux) [9] . Recently, the ecto-F1-ATPase was identified as a novel receptor of apoA-I in the liver [10] . Binding of apoA-I on ecto-F1-ATPase increases its hydrolase activity and leads to enhanced HDL endocytosis whereas the purinergic P2Y13 receptor was identified as the target of ADP produced by ecto-F1-ATPase [10] . (Fig. 1) is a schematic overview of the HDL pathway, the proteins (apolipoproteins, plasma enzymes, membrane transporters and recep-tors) involved, the physiologically relevant tissues and the various functions that contribute to atheroprotection.
The population of HDL particles in plasma is very heterogeneous in terms of size, shape and protein/lipid content. ApoA-I is the main protein component of all HDL particles, whereas apo -, apoE, apo -IV, apoM and apoC are only found in certain HDL sub-populations [11] . Proteomic studies identified more than 50 different proteins that are associated with HDL, some of which are proteins that are implicated in the anti-inflammatory functions of HDL [12, 13] . HDL lipids are also heterogeneous and include bioactive lipids such as phospho-sphingolipids, with sphingosine 1 phosphate (S1P) being the most physiologically important lipid molecule [14] . HDL also carries a great variety of quantitatively minor but bioactive lipids such as oxysterols and lysolipids. Plasma HDL can be separated by two dimensional gel electrophoresis into discrete subpopulations: pre-1, pre-2, 4, 3, 2 and 1. The larger 1, 2 particles may be associated with protection from cardiovascular disease [11] .
The pathway of HDL metabolism has been termed Reverse Cholesterol Transport (RCT) and this refers to the ability of HDL particles to transfer excess cholesterol from macrophages of the arterial wall to the liver for excretion to the feces thus contributing to atheroprotection. Although this is an attractive model that could account for the strongly negative association between plasma HDL cholesterol levels and risk for CAD, its value and especially the relationship between plasma HDL cholesterol and fecal cholesterol excretion, has been challenged by findings in both mice and humans (reviewed in [15] ). RCT can be measured experimentally both in vivo and ex vivo. For example, using a whole body RCT assay it was shown that ligands of liver X receptors and overexpression of apoA-I are potent stimulators of RCT in mice without affecting plasma HDL cholesterol levels [16, 17] . The method of whole body RCT developed by de Goma et al. (30) is using macrophages which are first loaded with radiolabeled cholesterol and subsequently are injected into the peritoneal cavity of mice. The accumulation of radiolabeled cholesterol in plasma, liver, and feces is then quantitated. An in vitro method to study RCT is the macrophage cholesterol efflux assay in which macrophages in culture are first loaded with radiolabeled cholesterol and then treated with purified apoA-I or reconstituted HDL (rHDL). The amount of radioactivity in the cells and the medium is then counted. The different approaches used to measure RCT in vitro and in vivo have been reviewed elsewhere [18] . The macrophage RCT assay has been proven to be valuable for the identi fication of proteins and lipids that play a role in the cholesterol efflux process, to evaluate the effect of drugs on HDL levels and in a clinical setting for the assessment of the functionality of HDL particles isolated from patients with diseases such as CAD, diabetes and rheumatoid arthritis.
HDL metabolism as described above can be regulated pharmacologically [19, 20] . Fibrates such as clofibrate and gemfibrozil have been used for decades as anti-lipidemic drugs but their beneficial effects on mortality is controversial [21, 22] . On average, fibrates increase HDL-C by 4.5% [22] . Their effects are mediated by the Peroxisome Proliferator Activated Receptors (PPARs) which regulate the transcription of various genes including apoA-I as described below. In a clinical study involving 234 patients with combined hyperlipidemia, both fenofibrate (FF) and gemifibrozil (GF) Fig. (1) . HDL metabolism and functions. Schematic representation of the pathway of HDL metabolism. The scheme shows: a) the proteins that play important roles in discrete steps of the pathway such as HDL biogenesis, remodeling and catabolism; b) the different subpopulations of HDL particles that are formed (poorly lipidated apoA-I, pre , , 1-4); c) the physiologically relevant organs or cell types (liver, intestine, macrophages, adrenals, endothelium); and d) the functions of HDL in each organ or cell type that contribute to atheroprotection.
reduced triglycerides and increased HDL-C to a similar extent but only FF treatment increased apoA-I plasma levels and this was in agreement with previous clinical trials [90, [93] [94] [95] . Niacin increases HDL-C levels by 15-30% but the mechanisms that are responsible for this upregulation are not very well understood [23] . Various models have been proposed based on ex vivo and in vivo studies such as niacinmediated inhibition of ATP synthase chain and HDL particles uptake by hepatocytes [24] , increase in the expression of PPAR , Conserved Domain 36 (CD36) and ABCA1 [25, 26] as well as reduction in hepatic expression and plasma levels of CETP [27] . Statins typically increase HDL-C levels by approximately 5% to 10% [28] . Although the mechanism(s) by which statins raise HDL-C remains unclear, by decreasing the number of apoB-containing lipoproteins statins appear to reduce the rates of CETP-mediated cholesteryl ester transfer to HDL [29] . Statins were also shown to increase apoA-I gene transcription by inhibiting the activity of the small GTPase RhoA and by activating PPAR [30] . The concept that CETP inhibition could be a promising HDL-C raising therapy was based on the observation that gene mutations in CETP were shown to increase HDL-C and apoA-I in humans with no evidence for premature atherosclerosis [31] . As discussed above, inhibition of CETP prevents the exchange of cholesteryl esters from HDL to VLDL/LDL particles and of triglycerides from VLDL/LDL to HDL causing a disturbance in HDL remodeling (Fig. 1) . CETP inhibitors such as anacetrapib, dalcetrapib and torcetrapib were shown to cause a drastic elevation in HDL-C levels in recent large clinical trials such as DEFINE (138% increase), dal-OUTCOMES (31-40% increase) and ILLUMINATE (72% increase) respectively but these studies failed to demonstrate a clinical benefit by CETP inhibition. These studies have been recently reviewed [20] . Through an epigenetic mechanism (competing with proteins bound to acetylated lysines in chromatin) the compound RVX-208 was shown to increase the production of apoA-I in hepatic cells [32] . However, in a recent trial (ASSERT) this compound had a minor impact on HDL-C levels (8% increase relative to placebo) and the primary outcome was not met [20] .
At the transcriptional level, members of the hormone nuclear receptor superfamily and notably the Liver X Receptors (LXRs) and the Peroxisome Proliferator Activated Receptor (PPARs) coordinate the expression of several genes in this pathway (e.g. apoA-I, ABCA1, ABCG1, apoE, CETP, SR-BI) in response to cholesterol or fatty acid accumulation [19, 20, 33] . Additional hormone nuclear receptors and hepatic transcription factors including Hepatocyte Nuclear factors 1, 4 and 3 also play coordinating roles in cholesterol metabolism as revealed by knock out or overexpression studies in mice. Their mechanisms of action are discussed extensively below. A novel mechanism of HDL regulation has recently been revealed with the identification of microRNAs (miRs) involved in lipid and lipoprotein metabolism at the posttranscriptional level and this topic has been covered by recent reviews [34] [35] [36] . Multiple genes in the HDL pathway have been shown to be under control of miRs including those affecting HDL biogenesis, cellular cholesterol efflux, selective cholesterol uptake and bile acid transport. HDL particles have also been shown to carry miRs along with them in the plasma suggesting that they may play novel roles in cell-cell communication [37] .
Most tissues are unable to biochemically degrade cholesterol and depend on efflux mechanisms via HDL to get rid of excess cholesterol and maintain a normal cholesterol homeostasis. Moreover, HDL exerts several protective effects on the endothelial cells of the arteries including inhibition of the expression of adhesion molecules and monocyte chemoattractant proteins such as MCP-1, induction of eNOS, inhibition of inflammatory cytokine signaling and inhibition of apoptosis [14, [38] [39] [40] . These effects were shown to be mediated by the interaction of apoA-I with SR-BI and by the interaction of S1P with its receptors (S1PR1-3) on the endothelial membranes (Fig. 1) [39, 41, 42] . HDL also protects LDL from oxidation in the intima by enzymes secreted by the macrophages [43, 44] . Importantly, all or some of the above functions of HDL are compromised in patients with CAD, diabetes and chronic inflammation [45] [46] [47] . In addition to having dysfunctional HDL, patients with CAD or diabetes are frequently characterized by dyslipidemia including high LDL and triglycerides (TG) and low HDL [48] . It was recently shown that the direct effects of HDL on endothelial cells isolated from patients with CAD and diabetes are markedly altered when compared to HDL from healthy subjects. Patients with diabetes have low levels of HDL cholesterol. HDL from these patients failed to stimulate endothelial cell NO production and to promote endothelial repair in a carotid artery injury model in mice [49] . The molecular mechanisms linking diabetes to low HDL levels are incompletely understood. Insulin signals via a cascade of intracellular effectors including Insulin Receptor Substrate (IRS), Phosphatidyl Inositol 3 Kinase (PI3K) and AKT [50] . Events downstream of AKT involve the activation of Forkhead Box (Fox) transcription factors such as Foxo1 and Foxa2 in macrophages and hepatocytes [51, 52] . Little is known about the effect of insulin on macrophages. The few available studies show that HDL-mediated cholesterol efflux from macrophages is inhibited by insulin a finding that could be translated to an enhanced foam cell formation in the atherosclerotic plaques of patients with hyperinsulinemia [53] .
Moreover, HDL from patients with either stable CAD or an acute coronary syndrome inhibited endothelial cell NO production and lost the ability to inhibit endothelial inflammatory activation as well as to promote endothelial repair in vivo [54] . During acute or chronic inflammation, several changes occur in HDLs. As part of the acute phase response, several plasma proteins carried in HDLs are decreased including apoA-I, Paraoxonase (PON), LCAT, CETP, and PLTP. The levels of HDL-associated serum amyloid A (SAA) and apoJ (clusterin) also increased several-fold in these subjects. In agreement with these biochemical findings, the prevalence of atherosclerosis is increased in rheumatic diseases, with the highest prevalence being in Systemic Lupus Erythematosous (SLE), followed by Reumatoid Arthritis (RA) (reviewed in [55] ).
Inflammatory bowel diseases (IBD) are a heterogeneous group of chronic inflammatory intestinal disorders which may also lead to systemic/extra-intestinal manifestations [56] . Several inflammatory mediators are involved in the pathogenesis of both IBD and atherosclerosis [57] . Studies have demonstrated that patients with IBD have a higher risk of developing early atherosclerosis and increased carotid intima-media thickness when compared with the general population [58] . Patients with IBD are characterized by chronic inflammation which is associated with lipid abnormalities including low levels of HDL cholesterol (HDL-C).
REGULATION OF HDL METABOLISM BY apoA-I: STUDIES IN EXPERIMENTAL ANIMALS
Mutations in the genes that participate in the early steps of the HDL pathway such as the apoA-I, ABCA1 and LCAT have a strong impact on HDL metabolism and affect greatly the structure and the concentration of HDL in plasma. In humans, inactivating mutations in apoA-I cause familial hypo-alpha lipoproteinemia by affecting one or more of the functional properties of apoA-I which include: a) activation of the enzyme LCAT which is responsible for HDL cholesterol esterification; b) interaction with ABCA1 and ABCG1 membrane transporters which is important for the transfer of cellular cholesterol to premature and mature HDL particles respectively; and, c) interaction with SR-BI which facilitates the selective HDL cholesterol uptake by hepatic and extrahepatic cells [11] .
Studies that were pioneered by V. Zannis group using adenovirus-mediated gene transfer of human apoA-I (wt and mutant) in apoA-I deficient mice were instrumental for the identification of residues in apoA-I that are critical for the above functions and for the functional characterization of natural or artificial mutation in apoA-I. These studies led to the identification of discrete steps where the pathway of biogenesis of HDL was inhibited or impaired [1, 11, 59] . For example, two naturally occurring mutants, the apoA-I[L141A]Pisa and apoA-I[L159R]Fin were thoroughly characterized in mice using adenovirus-mediated gene transfer [60, 61] . Both mutations are localized inside the LCAT activation domain and were anticipated to disrupt the interaction of apoA-I with LCAT and to inhibit HDL maturation to spherical particles. Human subjects hemizygotes for apoA-I I(L141R)Pisa had greatly decreased plasma apoA-I levels and near absence of HDL cholesterol, a profile very similar to Tangier patients [62] . First, using in vitro assays it was shown that both mutants had normal ability to promote ABCA1 mediated cholesterol efflux but greatly compromised capacity to activate LCAT. Adenovirus-mediated gene transfer showed that apoA-I -/-mice expressing either of the two mutants had greatly reduced HDL cholesterol and apoA-I levels. By two-dimensional gel electrophoresis of the plasma it was shown that only pre-and small size 4-HDL subpopulations were formed in these mice [60, 61] . Importantly, co-infection of apoA-I -/-mice with adenoviruses expressing either of the two apoA-I mutants and human LCAT increased plasma HDL cholesterol and apoA-I, generated spherical HDL and restored the normal pre--and -HDL sub-populations [60, 61] . The same methodology was used to characterize a large panel of bioengineered mutations in apoA-I and to provide novel insights into the structurefunction relationship in apoA-I and other apolipoproteins such as apoE [1, 59] . In order to assess the effect of the two naturally occurring mutations (Pisa and Fin) in atherosclerosis, we recently generated transgenic mice expressing either wt or mutant human apoA-I in a mouse apoA-I -/-background. Compared with the adenovirus system, transgenic mice offer unique opportunities to study not only short term but also the long term effects of apoA-I dysfunction in cholesterol metabolism and in atherosclerosis following a high fat diet. Our preliminary studies show that the lipid and lipoprotein phenotype of these Tg mice mimics the phenotype in humans with the same apoA-I mutations (Tiniakou et al., unpublished).
Several lines of evidence coming from studies in humans and experimental animals support the notion that plasma levels of HDL cholesterol are not a reliable predictor of CAD risk and premature atherosclerosis. For example, Tangier patients with inactivating mutations in ABCA1 have total absence of HDL in plasma but the predisposition to atherosclerosis is not as severe as anticipated and the same holds true for patients with mutations in the LCAT gene [15] . Recently, this notion was supported by the findings of a study in which three non-synonymous mutations in apoA-I (V11X, L144R, A164S) were identified by sequencing the coding region and exon-intron boundaries of the gene in 190 individuals with the 1% highest and 1% lowest HDL levels [63] . In the Copenhagen City Heart Study, twenty four, four and one unrelated individuals (carrier frequencies: 0.23%, 0.04% and 0.01%) were heterozygous for A164S, L144R and V11X, respectively. Heterozygotes for A164S had normal levels of HDL and apoA-I whereas in the other two heterozygotes plasma HDL and apoA-I levels were reduced by 40-50%. Using adenovirus-mediated gene transfer in mice we showed that mice expressing the A164S mutation had normal lipid and lipoprotein profile in plasma whereas mice expressing the L144R mutation had very low total cholesterol levels and decreased cholesteryl ester-to-total cholesterol ratio (CE/TC) indicating reduced LCAT activity [63] . Two-dimensional gel electrophoresis showed that the mutant apoA-I L144R promoted the formation of less mature, lipidpoor pre-and 4 HDL particles whereas WT apoA-I and the mutant apoA-I A164S both promoted the formation of normal pre-and a HDL subpopulations ( 1, 2, 3 and 4). Simultaneous treatment of mice with the adenovirus expressing apoA-IL144R and human LCAT normalized the total cholesterol level and the CE⁄TC, normalized the levels and the distribution of apoA-I in the HDL, restored normal preand HDL subpopulations and promoted the formation of spherical HDL particles. In summary, this was the first report of a mutation in apoA-I which predicts an increased risk of ischemic heart disease, myocardial infarction and total mortality in the general population independently of HDL cholesterol levels [63] .
GENETIC CAUSES OF HDL HETEROGENEITY
Mutations in the three genes described (apoA-I, ABCA1, LCAT) account for only 10% of the heterogeneity in plasma HDL levels [64] . Genome Wide Association Studies (GWAS) identified additional genetic loci that could influence plasma HDL levels. One of the genes that was identified in GWAS was the gene encoding for GALNT2 (ppGalNAc-T2). SNPs in intron 1 of GALNT2 were found to be associated with plasma HDL-C and triglyceride levels [65] . The enzyme belongs to a family of ppGalNAc transferases comprising 20 members in humans all catalyzing the transfer of GalNAc residues onto proteins, and thereby initiating mucin-type O-glycan synthesis on threonine and/or serine residues. It was shown that hepatic overexpression and silencing of GALNT2 in mice reduced and increased HDL-C levels, respectively [66] . Elegant work by the group of J. A. Kuivenhoven in Amsterdam showed that mutations in GALNT2 cause abnormal glycosylation of apoC-III which is an inhibitor of Lipoprotein Lipase (LPL) [67] . The abnormally lipidated apoC-III binds to LPL less efficiently and as a consequence LPL is more active to hydrolyze triglycerides in lipoproteins thus decreasing triglyceride rich lipoproteins in plasma and increasing HDL [67] . In a very recent interesting study by the same group it was shown that HDL heterogeneity in the human population has a polygenic origin [68] . They sequenced 195 genes with either established or implicated roles in lipid and lipoprotein metabolism plus 78 lipidunrelated genes in patients with HDL-C <1st (n=40) or >99th (n=40) percentile and the results were compared with 498 individuals representative of the Dutch general population and 95 subjects with normal HDL-C. The extreme HDL cohort carried more rare non-synonymous variants in the lipid gene set than both the general population and normal HDL-C cohorts. In the extreme HDL cohort, however, there was enrichment of rare non-synonymous variants in the lipid versus the control gene set and 70% of the lipid-related variants altered conserved nucleotides. In the most extreme cases, individuals were found to carry 12 or 14 rare variants simultaneously some of which are predicted to be potentially deleterious. This study indicated that even very extreme HDL-C phenotypes can have a polygenic origin. This complexity may explain why efforts to identify new HDL genes through linkage analyses have not been successful. Obtaining significant logarithm of odds (LOD) scores can be difficult in the face of genetic heterogeneity which characterizes the extreme HDL-C cohorts.
As discussed above, a promising strategy to increase HDL levels without compromising HDL functions is to upregulate apoA-I and ABCA1 genes in the liver which is the major organ of HDL synthesis contributing approximately 70% to plasma HDL levels. In the following paragraphs we will review the current knowledge on the mechanisms that regulate these two genes at the transcriptional level. The regulation of the apoM gene in the liver will also be reviewed in light of recent findings that apoM is the sole carrier of the bioactive phospholipid sphingosine 1 phosphate in HDL which is an important component of HDL-mediated atheroprotection [42] . The role of certain transcription factors in the regulation of HDL metabolism in general will also be discussed.
TRANSCRIPTIONAL REGULATION OF THE apoA-I GENE
The hypothesis that apoA-I overexpression could positively influence plasma HDL-C concentration has been validated experimentally in transgenic mice expressing human apoA-I under homologous or heterologous regulatory sequences. These mice have significantly elevated levels of HDL-C containing human apoA-I [69, 70] . These "humanized" apoA-I transgenic mice are valuable tools for the study of apoA-I gene regulation in vivo. Furthermore, it was demonstrated that overexpression of apoA-I in apoE KO or LDLR KO mice via transgene-or adenovirus-mediated gene transfer reduced atherosclerosis development confirming the anti-atherogenic role of apoA-I up regulation [71] [72] [73] .
In humans, the apoA-I gene is expressed abundantly in liver and intestine, and to a lesser extent in other tissues [74] . Previous studies had established that several members of the hormone nuclear receptor superfamily of transcription factors are major determinants of hepatic and intestinal apoA-I gene expression. Hormone nuclear receptors belong to a superfamily of transcription factors that are activated by steroid hormones (estrogens, androgens, glucocorticoids etc), retinoids, thyroids and products of intermediate metabolism such as bile acids, fatty acids, cholesterol derivatives etc [75] . Certain members of this family do not need ligand binding to regulate transcription and are classified as "orphans". Nuclear receptors are structurally highly conserved. The main structural features of hormone nuclear receptors are: an N-terminal transactivation domain called Activation Function 1 (AF-1), a conserved DNA binding domain that contains two zinc fingers, and a second transactivation domain called AF-2 located inside to the ligand binding domain (LBD) [76] . Nuclear receptors can bind to Hormone Response Elements (HREs) on the promoters of target genes either as homodimers or as heterodimers with the Retinoid X Receptor (RXR). The HREs consist of direct repeats (DRs), inverted repeats (IRs) or palindromic repeats (PRs) of the consensus sequence 5' AG(G/T)TCA 3'. The repeats are separated by 1, 2, 3, 4 or 5 nucleotides and are designated DR1, DR2 etc (for the direct repeats), IR1, IR2 etc (for the inverted repeats) and PR1, PR2 etc (for the palindromic repeats) [77, 78] . (Fig. 2) shows the mechanism of action of hormone nuclear receptors, their basic structural features and the consensus sequence of a typical HRE.
The proximal human apoA-I promoter spanning a region of 250 bp upstream of the transcription start site of the gene is sufficient to drive liver-specific gene expression both in cell cultures and in mice [79] [80] [81] . This promoter region is rich in nuclear factor binding sites and responds to various intracellular as well as extracellular ligands [82, 83] . Prominent role in the regulation of the apoA-I promoter play two Hormone Response Elements (HREs) located at positions -210/-190 and -132/-120 that bind members of the hormone nuclear receptor superfamily in a competitive manner (Fig.  3A) [81] . One of the factors that plays a prominent role in apoA-I gene regulation and HDL metabolism in general is Hepatocyte Nuclear Factor 4 (HNF-4) [81] .
THE ROLE OF HEPATOCYTE NUCLEAR FACTOR 4 IN HDL METABOLISM
HNF-4 was discovered as a factor present in rat liver nuclear extracts that interacts with the promoters of various liver-specific genes including transthyretin and apo-CIII [84] . In the adult organism, HNF-4 is expressed in the liver, kidney, intestine and pancreas [84] . In humans, heterozygous mutations in the HNF-4 gene are associated with an earlyonset form of type II diabetes called maturity onset diabetes of the young 1 (MODY 1) [85] . HNF-4 binds as a homodimer to the promoters of various genes involved in lipid and lipoprotein metabolism.
Experiments in genetically manipulated mice have illuminated the important role of HNF-4 in the generation and the maintenance of hepatic differentiation as well as for lipid and lipoprotein metabolism. Total disruption of the HNF-4 gene in mice leads to an embryonic lethal phenotype due to impairment of endodermal differentiation and gastrulation [86] . This early developmental arrest was rescued by the complementation of the HNF-4 -/-embryos with a tetraploid embryo-derived wild type visceral endoderm [87] . Analysis of the rescued mice showed that the expression of the apoA-I gene as well as of other apolipoprotein genes, shown previous to be regulated by HNF-4 including apoA-II, apoB, apoC-III and apoC-II, was abolished confirming the cell culture data [87] . Experiments in mice in which the HNF-4 gene was disrupted in the adult liver using Alb-Cre revealed that HNF-4 is essential not only for the establishment but also for the maintenance of hepatic differentiation [88] . HNF-4 loss caused an increase in liver weight mainly due to the accumulation of lipid droplets. This fatty liver phenotype could be accounted for by the loss of the expression of both apoB and microsomal triglyceride transfer protein (MTTP), two proteins that play key roles in VLDL secretion. Lipid and lipoprotein analysis of plasma of these mice revealed a dramatic reduction in total cholesterol, HDL cholesterol and triglycerides and a dramatic increase in the concentration of bile acids [88] . Furthermore, FPLC analysis showed that HDL cholesterol from the HNF-4 Liv KO mice eluted later than that from controls indicative of the presence of smaller HDL populations. Interestingly, the expression of the two essential genes for HDL biogenesis namely apoA-I and ABCA1 was not affected in the livers of the HNF-4 Liv KO suggesting that the reduction in the plasma HDL levels was the result of altered HDL remodeling rather than reduced biosynthesis. In agreement with this, the expression levels of the HDL receptor SR-BI was dramatically increased [88] . The increased levels of bile acids in the plasma could be accounted for by altered levels in the expression of genes of bile acid trafficking including bile acid export pump (BSEP) and sodium taurocholate co-transporter (NTCP). It was concluded that the main role of HNF-4 is to promote the net efflux of cholesterol from the liver and to control bile acid trafficking. It was subsequently shown that HNF-4 regulates the expression of the bile acid transporters ABCG5 and G8 in a coordinated fashion [89] .
THE ROLE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR A IN HDL METABOLISM
Studies in transgenic mice expressing the human apoA-I gene under its own regulatory sequences and clinical studies in humans have shown that fibrates exert a positive effect on apoA-I gene transcription as well as on plasma HDL levels [90] . The increase in human apoA-I gene transcription by fibrates is mediated by peroxisome proliferator-activated receptor (PPAR ) which binds to the HREs on the proxi- Fig. (2) . Mode of action of hormone nuclear receptors. Panel A: schematic representation of the mechanism of activation and function of a sub-family of hormone nuclear receptors, the heterodimers of Retinoid X receptors (RXRs) which includes several members such as the receptors for retinoic acid (RAR), thyroid hormone (T3), oxysterols (LXRs), fatty acids (PPARs) and bile acids (FXRs).All these receptors bind to DNA as obligatory heterodimers with RXR. Panel B: Domain structure of a typical hormone nuclear receptor. The structure is modular and consists of a n-terminal ligand-independent Activation Function 1 (AF-1) domain, a DNA binding domain of the zinc finger type and a composite domain consisting of the ligand binding, the dimerization and the Activation Function 2 (AF-2) domain. Nuclear receptors bind to DNA elements called Hormone Response Elements (HREs) in the promoters of target genes consisting of direct, inverted or palindromic repeats. The consensus sequence of a DR (Direct Repeat) HRE is shown at the bottom. Each receptor in the heterodimer occupies one halfrepeat and the type of the repeat determines binding specificity among nuclear receptors (for instance DR4 is preferred by LXR/RXR heterodimers).
mal apoA-I promoter as a heterodimer with RXR (Fig. 3A) [81, 91] . In vivo this was confirmed by experiments in mice that express human apoA-I under the control of its own promoter but lack the expression of PPAR . When these mice were given fenofibrate (FF) or gemfibrozil (GF) for 17 days an increase in plasma HDL-C levels was observed by FF and to a lesser extent by GF only in the mice that express endogenous PPAR [92] . The fibrate-treated mice had larger HDL particles possibly due to the up-regulation of phospholipid transfer protein and down-regulation of SR-BI [92] . Interestingly, the apoA-I gene cannot be up-regulated by fibrates in rodents due to a 3 base pair difference in the PPRE rendering the rodent apoA-I PPRE non-functional [93] . In line with the above findings, liver-specific inactivation of the PPAR heterodimer partner Retinoid X Receptor (RXR ) gene in mice was associated with increased expression of the apoA-I gene [94] .
LIVER RECEPTOR HOMOLOGUE 1 AND SMALL HETERODIMER PARTNER
In addition to HNF-4 and PPAR , the HREs of the proximal human apoA-I promoter bind apoA-I Regulatory Protein 1 (ARP-1) and Liver Receptor Homologue 1 (LRH-1) which repress and activate the apoA-I promoter, respectively (Fig. 3 ) [95, 96] . LRH-1 is a member of the Ftz-F1 subfamily of the hormone nuclear receptor gene superfamily [97] . It belongs to the orphan nuclear receptors, although its ligand-binding pocket can bind various phospholipids. It interacts with its cognate target sequence 5'-(Py)CAAGG(Py)C(Pu)-3'as a monomer [98] . It is highly expressed in liver, intestine, pancreas and ovary [98] [99] [100] . In the liver, LRH-1 plays a key role in cholesterol homeostasis, through the control of the expression of genes that are implicated in bile acid biosynthesis and enterohepatic circulation (CYP7A1, CYP8B1, ABCG5/8) [99, 101] , reverse cholesterol transport (SR-BI, apoA-I) and HDL remodeling (CETP) [96, 100, 102, 103] as well as in early development through the control of the expression of genes that are involved in embryonic development (Oct4) and of the hepatic nuclear factors HNF-3 , HNF-4 and HNF-1 [104, 105] .
OTHER NUCLEAR RECEPTORS IN apoA-I REGU-LATION
The two HREs of the apoA-I promoter also mediate the response of apoA-I to thyroids, retinoids and bile acids via heterodimers of Retinoid X Receptor (RXR ) with thyroid hormone receptor (TR ), Retinoic acid Receptor (RAR ) and farnesoid X receptor (FXR ), respectively (Fig. 3A ) [106, 107] . Although retinoids activate apoA-I gene expression, thyroids have dual effects on apoA-I promoter activity whereas bile acids inhibit apoA-I gene expression [81, [108] [109] [110] . It was shown that in response to bile acids FXR downregulates apoA-I gene transcription both by binding to the apoA-I HRE as well as by inducing small heterodimer partner (SHP) which in turn represses the activity of LRH-1 that binds to the same region [96] .
Ligands of the vitamin D receptor (VDR) were also shown to affect negatively apoA-I gene expression in hepatic cells [111] . In VDR KO mice serum HDL-C levels were 22% higher and the mRNA levels of ApoAI were 49.2% higher compared with WT mice. The mechanism by which VDR ligands affect HDL levels remains unclear [112] .
THE ROLE OF THE DISTAL ENHANCER IN apoA-I GENE EXPRESSION IN THE LIVER AND THE IN-TESTINE
The strength of the proximal apoA-I promoter in hepatic and intestinal cells was increased several-fold when it was fused to a 200 bp fragment upstream of the adjacent apoC-III gene [113] . This transcriptional enhancer domain contains HREs that bind HNF-4 and different combinations of liganddependent nuclear receptors as well as Specificity protein 1 (Sp1) [113, 114] . The contribution of the HREs and the Sp1 sites in the tissue-specific expression of the apoA-I gene in vivo was addressed using transgenic mice expressing either wild type or mutant forms of the proximal promoters and the enhancer [69, 115, 116] . A mutation in one of the two HREs of the enhancer (element I4) abolished the intestinal expression and reduced the hepatic expression of apoA-I to 20% of the WT control. Mutations in the two HREs of the proximal apoA-I promoter reduced the hepatic and intestinal expression of the apoA-I gene to approximately 15% of the WT control. Finally, combined mutations in the two HREs of the proximal apoA-I promoter and the HRE of the enhancer abolished the intestinal and hepatic expression of the apoA-I gene [117] . Studies in cell cultures established that HNF-4 and Sp1 factors are both required for the apoA-I promoter/enhancer communication by physically interacting with each other and forming transcriptional complexes in order to facilitate the recruitment of the basal transcriptional machinery [118] .
THE ROLE OF HEPATOCYTE NUCLEAR FACTOR 3 /FOXA2 IN HDL GENE REGULATION
The proximal apoA-I promoter contains one element that binds Hepatocyte Nuclear Factor 3 /Foxa2 [119, 120] . Foxa2 is a liver-enriched forkhead box transcription factor with a winged-helix DNA binding domain that binds to its consensus DNA sequence 5'-T(G/A)TTT(A/G)(C/T)T-3' as a monomer [121, 122] . In response to insulin signaling, Foxa2 transcriptional activity is inhibited through a mechanism that involves phosphorylation at threonine residue 156 by AKT/PKB kinase and nuclear exclusion [123, 124] .
Foxa2 is expressed mainly in the liver and also in pancreas, stomach, intestine and lung [125] and plays important roles in fetal development. Mice homozygous for a Foxa2 null mutation die in early embryogenesis shortly after gastrulation, show defects in node development and lack a notochord which leads to secondary defects in neural and foregut morphogenesis [126, 127] .
In addition to its critical role in embryonic development, Foxa2 also regulates lipid and glucose homeostasis in liver and pancreatic cells of adult mice [124, 128] . In the liver, Foxa2 has been shown to enhance fatty acid oxidation, ketogenesis and increased secretion of very low density lipoprotein and high density lipoprotein (VLDL and HDL) during fasting by activating the expression of key enzymes of these pathways [2, 124, 129, 130] . Using liver-specific gene ablation, it has been shown that Foxa2 plays an important role in bile acid homeostasis because it prevents cholestatic liver injury and ER stress after cholic acid diet by regulating multiple genes involved in bile acid metabolism [131] .
Several groups have used genome wide analysis such as ChIP-on-chip (chromatin immunoprecipitation followed by microarrays) and ChIP-Seq (chromatin immunoprecipitation followed by sequencing) to investigate the in vivo binding sites of Foxa2 in the adult mouse liver or liver-derived cells (HepG2).
Wolfrum et al., generated gene chip expression profiles from livers of wild type mice that had been infected with adenoviruses expressing either GFP or a constitutively active form of Foxa2 that cannot be phosphorylated by AKT kinase (Foxa2-T156A) and they observed robust increases in the expression of genes involved in HDL metabolism (SR-BI, HNF-4 ), triglyceride degradation (LPL, LIPC), -oxidation, ketogenesis and glycolysis [124] . In another ChIP-Seq analysis, approximately 11,000 Foxa2 binding sites were identified in the adult mouse liver. The majority of these binding sites were localized within 10 kb upstream of the transcription start sites of genes and within the first introns. It was found that 43.5% of genes expressed in the liver were also associated with at least one Foxa2 binding site, including genes of HDL metabolism (apoA-I, apoB, HNF-4 , LPL), with the greatest enrichment of 30-fold for apoA-II [132] .
Studies by the group of K. Kaestner have used ChIP-Seq and Chip-on-chip analysis in samples of livers of wild type and hepatocyte specific Foxa2 knockout mice (Foxa2 loxP/loxP Alfp-Cre) [131, 133, 134] . They identified 574 enhancer and promoter regions, corresponding to 484 unique genes, occupied by Foxa2 and clustered in categories of genes involved in lipid and steroid metabolism such as ABCA1, ABCC2, apoA-I, apoE, LIPC, LDLR [131] . Furthermore, in Foxa2-deficient mice fed with CA diet, the expression of genes involved in lipid metabolism-transport (ABCG8, LCAT, LIPC, LPL, PLTP) was significantly reduced where as the expression of apoB gene was increased [133] .
ChIP-Seq studies in HepG2 cells identified binding sites for Foxa2 in genes associated with HDL metabolism such as apoA-I , apoA-II, apoA-IV, hepatic lipase (LIPC), LDL receptor (LDLR), phospholipid transfer protein (PLTP) and nuclear receptors HNF1 , HNF1 , HNF4 and RXR thus confirming the role of Foxa2 in HDL metabolism [122, 135] .
TRANSCRIPTIONAL REGULATION OF THE ABCA1 GENE BY LXRs
The gene encoding the ABCA1 is expressed in the liver, small intestine, macrophages, kidney and various other tissues [136] [137] [138] [139] . ABCA1 is an important regulator of HDL biogenesis in the liver and facilitates the removal of excess cholesterol from macrophages. Thus, studies on the control of its expression have been mostly focused on these two physiologically relevant cell types.
The expression of the ABCA1 gene is controlled primarily by the levels of intracellular cholesterol. When the levels of cellular cholesterol increase, certain products of cholesterol hydroxylation such as 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(S),25-epoxycholesterol, 20(S)-hydroxycholesterol, and 27-hydroxycholesterol act as natural agonists of Liver X Receptors (LXRs). LXRs along with SREBPs are the key cholesterol sensing transcription factors in the cell and as a consequence, most of their target genes have major roles in intracellular and plasma cholesterol homeostasis [33, [140] [141] [142] . There are two LXR isoforms, LXR and LXR , sharing almost 80% amino acid identity in their DNA-binding and ligand-binding domains. LXRs bind to LXR response elements (LXREs) of the DR4 type (direct repeats separated by 4 nucleotides) as obligatory heterodimers with the retinoid receptor RXR [141] . Synthetic LXR ligands such as T0901317 and GW3965 are currently used widely as tools for the assessment of LXR signaling and for the identification of novel LXR target genes [143, 144] . Experiments in mice have shown that synthetic LXR ligands up-regulate ABCA1 gene transcription, increase plasma HDL levels and promote cholesterol efflux from macrophage cultures [145] . However, LXRs are strong inducers of hepatic lipogenesis due to the transcriptional up-regulation of SREBP-1c gene [146, 147] . Thus, treatment of mice with synthetic LXR agonists elevates triglyceride levels in the liver and in the plasma [143] . On top of their role as cholesterol sensors, in macrophages LXRs have been shown to suppress inflammatory signalling pathways via a mechanism of transrepression [148] In HDL metabolism LXRs play an important role by coordinately regulating the expression of several genes including ABCA1, ABCG1, SR-BI, PLTP and CETP [33] . Given the strong impact of LXRs on Reverse Cholesterol Transport [16] , it should be anticipated that natural or synthetic LXR agonists should increase HDL-C levels in plasma. However, LXRs also activate the transcription of CETP leading to a cholesterol transfer from HDL to LDL and VLDL particles and a reduction in HDL concentration [149] . Therefore, studies in mice on the effects of LXR agonists on the lipid and lipoprotein profiles have to be interpreted with caution because mice lack CETP. Thus, T0901317 was able to elevate HDL-C levels in wild-type mice while it decreased HDL-C levels in CETP transgenic mice and cynomolgus monkeys [149] [150] [151] .
The ABCA1 promoter upstream of exon 1 contains a LXRE of the DR4 type at position -62/-47 ( Fig. 3B) [152] . In addition to serving as a LXRE, the same DR4 element of the ABCA1 promoter has been shown to bind RXR/retinoic acid receptor (RAR) and RXR/thyroid hormone receptor (T3R) heterodimers and to mediate the activation or the repression of ABCA1 transcription by retinoic acid and thyroid hormone, respectively [153, 154] . Recently, it was shown that niacin treatment of HepG2 cells caused an increase in ABCA1 promoter activity and that the LXRE was required for niacin-mediated ABCA1 up-regulation [26] . The mechanism by which niacin activates ABCA1 gene transcription was not studied further but based on previous findings [25] it was hypothesized that niacin treatment increases oxysterols which subsequently activate LXRs. If this hypothesis is correct, it would be anticipated that niacin should have a global impact on the regulation of LXR target genes.
We have shown that the oxysterol/retinoid-induced transcription of the ABCA1 gene in hepatic cells is modulated by the ubiquitous transcription factor Sp1 that binds to the proximal ABCA1 promoter, adjacently to the LXRE [155] . Sp1 inhibition by mithramycin blocked the induction of the ABCA1 gene by oxysterols/retinoids as well as the ligandinducible recruitment of Sp1 and RXR /LXR heterodimers to the ABCA1 promoter. LXR and Sp1 were shown to interact physically both in vitro and ex vivo. This study revealed a novel mechanism of regulation of the human ABCA1 transporter which involves synergistic interactions between oxysterol/retinoid-inducible hormone nuclear receptors and the transcription factor Sp1 [155] . An additional but not thoroughly characterized LXRE is present at the intron 1 promoter of the ABCA1 gene [156] .
Whereas cholesterol accumulation leads to ABCA1 gene induction via the oxysterol/LXR pathway, cholesterol depletion which leads to activation of the sterol regulatory element binding protein 2 (SREBP-2), represses the activity of the ABCA1 promoter via binding of SREBP-2 to an E-box element [103] . The same E-box serves as a binding site for Upstream Stimulatory Factors (USFs) 1 and 2, which also repress the ABCA1 promoter [104, 105] . The ABCA1 promoter also contains a binding site for the zinc finger protein ZNF202 (GT box), which acts a repressor of ABCA1 gene expression (Fig. 3B) [106, 107] .
MECHANISMS OF apoM GENE REGULATION IN THE LIVER
Apolipoprotein M (apoM) is a glycoprotein that belongs to the lipocalin protein family [157, 158] . It is synthesized and secreted primarily by the liver and kidney and associates with HDL particles through its N-terminal signal peptide which is retained following secretion [159, 160] . In mice, silencing of the endogenous apoM gene via small interfering RNA technology was associated with the loss of pre--HDL particles and the formation of larger HDL particles suggesting that apoM may play a role in HDL maturation [161] . Overexpression of apoM in LDL receptor knockout mice via adenovirus reduced atherosclerosis development [2, 162] . Furthermore, apoM-containing HDL particles isolated from human plasma or apoM transgenic mice have been shown to be more resistant to oxidation and more efficient in protecting against LDL oxidation as well as stimulating cholesterol efflux from macrophages [162, 163] .
The expression of apoM in the liver is primarily controlled by Hepatocyte Nuclear Factor-1 (HNF-1 ) [164] . HNF-1 belongs to the homeodomain transcription factor family and regulates gene transcription via binding to target sites that are identical or homologous with the consensus sequence 5'-ATTAACCATTAA-3' as a homodimer or heterodimer with its isoform vHNF-1/HNF-1 [165] . HNF-1a is primarily expressed in the liver, intestine, kidney and the exocrine pancreas where it plays important roles in development, cell differentiation and metabolism [165] . In humans, mutations in HNF-1a cause maturity-onset diabetes mellitus of the young type 3 (MODY 3) that is characterized by impaired insulin secretion due to defects in pancreatic cells [166] .
HNF-1
-/-mice have complete absence of apoM in plasma whereas the concentration of other apolipoproteins is either similar (apoA-II, apoB, apoC) or increased (apoA-I, apoE) compared to wild type mice but this was not due to the absence of apoM as restoration of apoM gene expression in the liver via adenovirus-mediated gene transfer could not rescue the abnormal apolipoprotein profile [161] .
HNF1
-/-mice exhibit hepatic, pancreatic and renal dysfunctions such as liver enlargement and extensive hypercholesterolemia and hyperphenylalaninemia, defective bile acid transport and increased bile acid and hepatic cholesterol synthesis, impaired HDL metabolism and glucose homeostasis [165] . Shih et al. analyzed the plasma lipoprotein profile of HNF-1 -/-mice and found that plasma cholesterol was distributed in the HDL fraction and to an abnormal apoE-enriched HDL fraction that was identified as HDLc or HDL1 (large HDL fraction) suggesting that this abnormal lipid profile in HNF-1 -/-mice may be due to the lack of apoM [167] .
HNF-1 regulates apoM gene expression through direct binding to a conserved DNA element located in the proximal apoM promoter region between nucleotides -55 to -41 in humans and -103 to -88 in mice [164] . Interestingly, this site overlaps with a DNA sequence element that is homologous to the consensus binding site for members of the proinflammatory transcription factors c-Jun and JunB (Fig. 3C) .
ApoM gene expression is negatively regulated during inflammation and the acute phase response. Treatment of hepatoma cells with stimuli that produce systemic inflammation such as lipopolysacharide (LPS) or with pro-inflammatory cytokines (Tumor Necrosis Factor or Interleukin 1 ) was shown to decrease apoM mRNA levels in the liver [168] . These data indicate that apoM, similarly to other apolipoproteins such as apoA-I or apoC-III is a negative acute response protein and its levels decrease during infection and inflammation.
We showed recently that the HNF-1 binding element in the proximal human apoM promoter serves as a dual specificity regulatory element that mediates activation or repression of apoM promoter activity by HNF-1 and Jun proteins respectively in hepatic cells (Fig. 3C) [169] . The experimental evidence that supports the dual functionality of this element of the apoM promoter was the following: a) Jun proteins repressed apoM promoter activity only in cells expressing HNF-1 . Jun-mediated repression was abolished in HepG2 cells in which endogenous HNF-1 expression had been silenced by specific shRNAs; b) the mouse apoM promoter does not contain a functional AP-1 site due to single nucleotide difference but it retains a functional HNF-1 responsive element; c) competition experiments showed that binding of Jun proteins and HNF-1 to the apoM promoter is mutually exclusive d) chromatin immunoprecipitation assays established that AP-1 activation leads to the recruitment of cJun and Jun B proteins to the proximal apoM promoter with the simultaneous displacement of HNF-1.
Interestingly an identical mechanism of Jun-mediated repression of promoter activity via dual specificity AP-1/HNF-1 responsive element operates on the promoter of the human apolipoprotein A-II gene, the expression of which is also under negative regulation during the acute phase response [169] . Furthermore, Jun proteins have been shown to repress the activity of the human apolipoprotein C-III [170] , apoE [171] and ABCA1 (Mosialou and Kardassis unpublished) promoters in hepatic cells suggesting a broader role of AP1 factors in lipoprotein metabolism in the liver during inflammation. The pathways leading to apolipoprotein gene downregulation by pro-inflammatory Jun factors remain poorly characterized, however the existing evidence supports important roles of Protein Kinase C, C-Jun N Terminal Kinase (JNK) and Tpl2 (MEKK3) [169, 171] .
In addition to HNF-1 , apoM gene transcription in the liver has been shown to be controlled positively by Liver Receptor Homolog-1 (LRH-1) and Forkhead box A2 (FOXA2) transcription factors which bind to distinct sites on the proximal apoM promoter [2, 172] . LRH-1 stimulates apoM gene transcription by binding to an LRH-1 response element located in the proximal human apoM promoter [172] . Small heterodimer partner (SHP), an atypical orphan nuclear receptor that lacks a DNA-binding domain, inhibits the transactivation function of LRH-1 by direct interaction with its AF-2 activation domain thus competing with the binding of co-activators. Overexpression of SHP or induction of its expression by bile acids (ligands for the nuclear receptor Farnesoid X Receptor, FXR), strongly increased SHP association to the apoM promoter resulting in reduced apoM gene expression levels [172] . Similarly, apoM expression was reduced in the liver of mice fed with a diet supplemented with cholic acid or in the liver of SHP transgenic mice [172] . Thus, bile acids suppress apoM expression in vivo by inhibiting LRH-1 transcriptional activity via recruitment of SHP to the apoM promoter (Fig. 3C) .
Haploinsufficient Foxa2 or hyperinsulinemic mice exhibited decreased apoM expression and plasma pre-HDL levels due to inactivation of Foxa2. Leptin treatment of ob/ob (leptin deficient) and db/db (leptin receptor deficient) mice restored apoM expression through relocation of Foxa2 to the nucleus [2] . Foxa2 is recruited to a conserved binding site on the human apoM promoter located between nucleotides -398 and -388 (Fig. 3C) [2] . Preliminary data from our group indicate that Foxa2 plays a wider role in HDL metabolism by regulating in a positive or a negative manner, the expression of several HDL genes in hepatic cells. Foxa2 negatively regulates the human ABCA1 promoter by binding to three sites in the proximal region, one of which is the TATA box (Thymiakou and Kardassis, submitted).
In agreement with the role of Foxa2 in apoM gene regulation, insulin, insulin-like growth factor I (IGF-I) and IGF-I potential peptide (IGF-IPP) significantly inhibited apoM gene expression in a dose-and time-dependent manner in HepG2 cells and in primary human and murine hepatocytes [173] . The inhibitory effect of insulin was mediated through the activation of phosphatidylinositol-3-kinase (PI3K) that in turn activates PKB resulting in inactivation of Foxa2 [173] . Furthermore, glucose strongly inhibited apoM gene expression in HepG2 cells and the inhibitory effects of glucose and insulin were additive while in rats rendered hyperglycemic by short-term glucose infusion, resulting in enhanced insulin secretion, serum apoM concentrations and hepatic apoM mRNA levels were significantly reduced [174] .
We showed that apoM gene is under the control of hormone nuclear receptors that play pivotal roles in lipid and glucose metabolism [175] . Among these nuclear receptors, HNF-4 seems to play a major role in the regulation of apoM gene expression in the liver. This is in agreement with a previous cDNA microarray analysis of HNF-4-induced genes in human hepatoma cells that showed a 4.5-fold increase in apoM expression levels by overexpressed HNF-4 [176] . Overexpression via adenovirus mediated gene transfer and siRNA-mediated gene silencing established that hepatocyte nuclear factor 4 (HNF-4) is an important regulator of apoM gene transcription in hepatic cells. ApoM promoter deletion analysis combined with DNA affinity precipitation and chromatin immunoprecipitation assays revealed that HNF-4 binds to a hormone-response element in the proximal apoM promoter (nucleotides -33 to -21) [175] . Mutagenesis of this HRE decreased basal hepatic apoM promoter activity to 10% of control and abolished the HNF4-mediated transactivation of the apoM promoter. In addition to HNF-4, homodimers of retinoid X receptor and heterodimers of retinoid X receptor with receptors for retinoic acid, thyroid hormone, fibrates (peroxisome proliferator-activated receptor), and oxysterols (liver X receptor) were shown to bind with different affinities to the proximal HRE in vitro and in vivo. Ligands of these receptors strongly induced human apoM gene transcription and apoM promoter activity in HepG2 cells, whereas mutations in the proximal HRE abolished this induction. These findings provide novel insights into the role of apoM in the regulation of HDL by steroid hormones.
CONCLUSIONS
HDL is an attractive target for the development of therapies for CAD due to its multiple atheroprotective functions in several cell types such as the macrophages and the endothelium. The current status of HDL-based clinical trials has been recently reviewed [20] . Despite the recent disappointments from clinical trials aiming to prevent CAD events by HDL-raising strategies (CETP inhibitors, niacin, RVX-208) and the failure of genetics to correlate HDL levels with CAD events [177] the HDL hypothesis has not been abandoned yet. The challenges now are to develop novel therapies that would raise HDL without compromising HDL functionality, to achieve as much specificity towards HDL as possible and to capitalize on the functions of HDL.
As discussed above, drugs that could specifically increase the expression of apoA-I or ABCA1 are anticipated to be of great clinical benefit because they will increase the rate of HDL biogenesis and of RCT and such drugs do not exist yet. All studies that have been performed to date in experimental animals (i.e. using Tg mice) indicate that HDL structure or functionality is not affected by apoA-I or ABCA1 upregulation. In order to develop such drugs, we need to understand in depth the molecular mechanisms (regulatory elements and transcription factors) that control the expression of these two genes in hepatic cells. This knowledge on gene regulation will also allow us to understand better the significance of polymorphisms or mutations in regulatory regions of HDL genes and their association with disease as we have done recently in the cases of ABCG1 and LXR [178, 179] . The identification of Foxa2 as a transcription factor that coordinately regulates the expression of genes involved in both lipid and glucose metabolism in response to insulin offers new opportunities to dissect the molecular mechanisms that link dyslipidemia with diabetes. Regarding LXR-based therapies, the current ligands greatly enhance RCT in vitro and in vivo but are of no clinical value due to their severe lipogenic effects in the liver. Thus the development of novel isoform and hopefully target-specific drugs is anticipated. Novel agonists of PPARs are also anticipated. Understanding how HDL genes are regulated by inflammatory factors will enable us to develop novel tools to reduce the atherosclerotic burden in patients with chronic inflammatory diseases. For example, the identification of AP1 (c-Jun, JunB) proteins as negative regulators of several genes involved in HDL metabolism (ABCA1, apoM, apoA-II, apoE) provides new opportunities towards this goal.
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